Uchida Mayako, Mori Yasuhiro, Akiba Kenta, Miyasaka Moena, Hirano Tatsuya, Ikesue Hiroaki, Yamaguchi Yuki, Takano Aoi, Maegawa Nami, Shimomura Yoshimitsu, Hosohata Keiko, Muroi Nobuyuki, Ishikawa Takayuki, Hashida Tohru, Nakamura Tsutomu
Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences.
Department of Pharmacy, Kobe City Medical Center General Hospital.
Biol Pharm Bull. 2020 Oct 1;43(10):1577-1582. doi: 10.1248/bpb.b20-00428. Epub 2020 Aug 14.
Bendamustine plays an especially important role as a treatment for non-Hodgkin lymphoma (NHL). However, patients administered bendamustine alone or in combination with rituximab (BR) may experience drug-associated skin toxicities that can profoundly impact their health-related QOL through both physical discomfort and psychological distress. Moreover, worsening skin symptoms may lead to dose reduction or termination in the management of cancer chemotherapy. We retrospectively investigated patient backgrounds and pretreatment characteristics from medical records of NHL patients treated with bendamustine alone or BR therapy and identified predictive factors for skin toxicities at the start of chemotherapy. Patients were eligible for the study if they were 20 years older, diagnosed with NHL, and received bendamustine alone or BR therapy at the Department of Hematology, Kobe City Medical Center General Hospital, between April 1, 2011, and March 31, 2018. This study included 95 patients with newly diagnosed or refractory or relapsed NHL. Multivariate stepwise logistic regression analysis with backward selection revealed that baseline non-prior chemotherapy (odds ratio (OR), 15.72; 95% confidence interval (CI), 4.24-83.13, p < 0.001) was a significant factor influencing the occurrence of skin toxicity. Our results demonstrated that non-prior chemotherapy was a significant risk factor for skin toxicities in patients with NHL receiving bendamustine alone or BR therapy. No patient experience serious side effects of grade 3 or higher and that bendamustine is very useful as a first-line treatment.
苯达莫司汀在非霍奇金淋巴瘤（NHL）的治疗中发挥着尤为重要的作用。然而，单独使用苯达莫司汀或与利妥昔单抗联合使用（BR）的患者可能会出现与药物相关的皮肤毒性，这可能通过身体不适和心理困扰对其健康相关生活质量产生深远影响。此外，皮肤症状的恶化可能导致癌症化疗管理中的剂量减少或终止。我们回顾性研究了单独接受苯达莫司汀或BR治疗的NHL患者的病历中的患者背景和预处理特征，并确定了化疗开始时皮肤毒性的预测因素。如果患者年龄在20岁及以上，被诊断为NHL，并于2011年4月1日至2018年3月31日在神户市立医疗中心总医院血液科接受单独的苯达莫司汀或BR治疗，则符合该研究的条件。本研究纳入了95例新诊断、难治性或复发性NHL患者。采用向后选择的多变量逐步逻辑回归分析显示，基线时未接受过化疗（优势比（OR），15.72；95%置信区间（CI），4.24 - 83.13，p < 0.001）是影响皮肤毒性发生的一个重要因素。我们的结果表明，未接受过化疗是接受单独苯达莫司汀或BR治疗的NHL患者发生皮肤毒性的一个重要危险因素。没有患者出现3级或更高等级的严重副作用，并且苯达莫司汀作为一线治疗非常有用。
